VJHemOnc Podcast

iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, University of British Columbia, Vancouver, Canada, Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, and Sven De Vos, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, discuss novel therapies in NHL, drawing focus on the role of antibody-drug conjugates (ADCs).

MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.

In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.

iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, share some insights into the evolving treatment landscape in mantle cell lymphoma (MCL), commenting on the changing role of transplantation and the impact of novel agents.

iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

 

In this podcast, Francine Foss, MD, Yale School of Medicine, New Haven, CT, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Francois Lemonnier, MD, PhD, Henri Mondor University Hospital, Créteil, France, and Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discuss recent updates in the biology and treatment of T-cell lymphoma.

iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discuss the most recent updates in transplantation and immunotherapies in AML, and further comment on how to improve outcomes for patients.

Classifying frailty and approaching elderly patients with lymphoma

While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area of research.

In this podcast, Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, and Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discuss challenges with classifying frailty in elderly patients with diffuse large B-cell lymphoma (DLBCL) and HL, as well as treatment options available to these patients.

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Scoring System (IPSS-M). 

In this podcast, you will hear from Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, who discuss recent updates in the diagnosis, risk stratification and treatment of LR-MDS. This discussion was filmed at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

iwAL 2023 Session III: The relevance of TP53 mutation in AML

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Andrew Wei, MBBS, PhD, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Australia, and Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the relevance of TP53 mutation in AML, highlighting prognostic approaches and therapeutic strategies for this patient population. 

iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Harry Erba, MD, PhD, Duke University, Durham, NC, and Jessica Altman, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discuss new treatments in AML, drawing focus on FLT3 inhibitors, novel combinations, and treating patients with relapsed disease.

iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX, Uma Borate, MBBS, The Ohio State University Comprehensive Cancer Center, Columbus, OH, and Koichi Takahashi, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss clonal hematopoiesis (CH) in AML, early detection and intervention, and potential therapeutic strategies.